Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.
Buti S, Basso U, Giannarelli D, De Giorgi U, Maruzzo M, Iacovelli R, Galli L, Porta C, Carrozza F, Procopio G, Fonarini G, Lo Re G, Santoni M, Sabbatini R, Cusmai A, Zucali PA, Aschele C, Baldini E, Zafarana E, Favaretto A, Leo S, Hamzaj A, Mirabelli R, Nole' F, Zai S, Chini C, Masini C, Fatigoni S, Rocchi A, Tamburini E, Cortellini A, Bersanelli M. Buti S, et al. Among authors: bersanelli m. J Immunother. 2023 Jan 1;46(1):22-26. doi: 10.1097/CJI.0000000000000446. Epub 2022 Nov 4. J Immunother. 2023. PMID: 36472582 Free PMC article.
Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Buti S, et al. Among authors: bersanelli m. Anticancer Drugs. 2013 Jul;24(6):535-54. doi: 10.1097/CAD.0b013e3283609ec1. Anticancer Drugs. 2013. PMID: 23552469 Review.
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Santoni M, et al. Among authors: bersanelli m. Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559290
Systemic adjuvant therapies in renal cell carcinoma.
Buti S, Bersanelli M, Donini M, Ardizzoni A. Buti S, et al. Among authors: bersanelli m. Oncol Rev. 2012 Oct 8;6(2):e18. doi: 10.4081/oncol.2012.e18. eCollection 2012 Oct 2. Oncol Rev. 2012. PMID: 25992216 Free PMC article. Review.
Combination therapy in kidney cancer: the next revolution?
Buti S, Bersanelli M. Buti S, et al. Among authors: bersanelli m. Lancet Oncol. 2015 Nov;16(15):1441-1442. doi: 10.1016/S1470-2045(15)00325-3. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26482275 No abstract available.
175 results